Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US court backs Kabi’s retreat from US$4.75bn Akorn merger

Executive Summary

Fresenius Kabi has won a legal battle absolving the company of completing its US$4.75 billion merger agreement with Akorn, with a US court ruling that the German firm had proper grounds to back away from the deal. The US-based ophthalmics and injectables firm, which had filed suit in order to compel Kabi to consummate the transaction, intends to appeal the ruling, while Kabi acknowledged that “the judgement is not yet final”.

You may also be interested in...



Akorn's Delay Moving Three Generics To OTC Leads To $7.9M Settlement In Medicare Billing Complaint

Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage. 

Akorn Pays Out $7.9m In Medicare Fraudulent Billing Case

Akorn has agreed to pay out $7.9m to settle allegations that it deliberately sold three generic drugs as prescription-only when they should have been classed as over-the-counter, in a deal with the US Department of Justice. The mislabeling led Medicare Part D to pay out for the drugs for around a year despite the products not being eligible for Medicare coverage.

Fresenius Kabi Braced For ‘Pyrrhic Victory’ In Akorn Damages Lawsuit

Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.

Latest News
See All
UsernamePublicRestriction

Register

GB001267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel